Changes in Hong Kong stocks | Wangshan Wangshui-B (02630) rose more than 15% in the afternoon and recently signed a licensing agreement with Xiansheng Pharmaceutical for new indications of VV116

The Zhitong Finance App learned that Wangshan Wangshui-B (02630) rose more than 15% in the afternoon. As of press release, it had risen 14.81% to HK$88, with a turnover of HK$133.12 million.

According to the news, Wangshan Wangshui issued an announcement at the beginning of this month to sign a license agreement with Xiansheng Pharmaceutical for the new indications of VV116. Under the agreement, Xiansheng Pharmaceutical will obtain exclusive licensing rights for remidvir deuterium hydrobromide suspension for use against respiratory syncytial virus (RSV) infection and human metapulmonary virus (HMPV) infection indications in Greater China. Wangshan Wangshui and Xiansheng Pharmaceutical have joined forces to accelerate the clinical development and commercialization process of VV116 to benefit more patients by leveraging their respective R&D, production and commercialization advantages.

According to public information, Wangshan Wangshui focuses on three major treatment areas: neuropsychiatry, reproductive health, and viral infections. As of October 21, 2025, the company has built 9 diversified innovation pipelines, of which 2 are in the commercialization stage, 4 are in the clinical stage, and 3 are in the pre-clinical stage. In addition to innovative drug pipelines, the company is also developing a generic drug segment, with 3 of these drugs being commercialized or close to commercialization. Currently, Wangshan Wangshui's two core products are LV232 and TPN171, respectively.